Introduction
Immunotherapy with interferon-(IFN-) is used for treating patients with chronic hepatitis C. The adverse effects of IFN--based immunotherapy comprise major depression and depressive symptoms, such as expressed and unexpressed sadness, irritability, insomnia, loss of appetite, asthenia, loss of interest, slowness, anxiety, social withdrawal, and lack of concentration.There is now evidence that major depression is associated with an activation of the inflammatory response system (IRS) such as increased production of proinflammatory cytokines, such as interleukin-1 (IL-1 ), IL-6, and IFN-. IRS activation and administration of proinflammatory cytokines may induce depressive symptoms through their modulation of, among other things, the central and peripheral serotonergic system. It has been hypothesized that, in depression, reduced plasma tryptophan is related to activation of the IRS. One explanation is that indoleamine 2,3-dioxygenase (IDO), a major tryptophancatabolizing enzyme, is induced during IRS activation by proinflammatory cytokines, such as IFN-and IL-2. No research has examined the effects of IFN--based immunotherapy on plasma tryptophan in relation to its major catabolite in the IDO pathway, i.e., kynurenine, and on serum 5-HT concentrations. The aims of this study were to examine (1) whether immunotherapy with IFN-in patients with hepatitis C decreases serum 5-HT concentrations and induces the catabolism of tryptophan and, subsequently, causes reductions in plasma tryptophan and increases in serum kynurenine; and 2) whether there are associations between the immunotherapy-induced changes in depressive symptoms and in the metabolism of 5-HT.
Methods

Patients
Eighteen patients (10 men and 8 women; mean age ± SD, 40.5 ± 11.5 years) affected by chronic active hepatitis C were recruited from the hepatology clinic at the I Medical Clinic, University of Rome La Sapienza from November 1997 to May 1998. Three of the 18 patients suspended IFN-therapy soon after starting treatment. Fasting (overnight) plasma or serum for the assay of amino acids, 5-HT, and kynurenine was always collected at 8:00 a.m. at baseline (before starting treatment) and 2, 4, 16, and 24 weeks after starting IFN--based immunotherapy. During each of these sessions, patients completed the Montgomery-Asberg Depression Rating Scale (MADRS) and the Hamilton Rating Scale for Anxiety (HAM-A). High-performance liquid chromatography (HPLC) was used to measure plasma tryptophan as well as the amino acids known to compete with the same cerebral transport system, i.e., valine, leucine, tyrosine, phenylalanine, and isoleucine. The tryptophan/valine + leucine + isoleucine + tyrosine + phenylalanine (CAA) was computed and multiplied by 100 as an index of the availability of plasma tryptophan to the brain. Serum 5-HT (Biorad, Eke, Nazareth, Belgium) was determined by means of HPLC. Serum kynurenine was determined by means of HPLC as described by Holmes. The kynurenine per tryptophan quotient (K/T) was computed, because this ratio allows us to estimate IDO activity.
Statistics
Group mean differences were ascertained by means of analysis of variance (ANOVA). Repeated measure (RM) design ANOVAs were used to check the effects of IFN-immunotherapy on the clinical and biochemical measurements. A priori comparisons among treatment means were ascertained with the Dunn test. Tests on simple effects were performed to examine significant main effects or significant interaction patterns. Correlations between variables were assessed by means of Pearson's product moment correlation coefficients. Time relationships were computed by means of regression analyses, which were pooled over the repeated measurements in the subjects. Table 1 . Measurements of the Montgomery Asberg Depression Rating Scale (MADRS) and the Hamilton-Anxiety (HAM-A) scale, serum serotonin (5-HT), plasma tryptophan, serum kynurenine and the kynurenine per tryptophan (K/T) quotient, the sum of the 5 competing amino acids (CAA) and the tryptophan/CAA ratio in hepatitis C patients before starting treatment (baseline), and after 2-4 weeks and 4-6 months of interferon-alpha-based immunotherapy Table 1 shows significant effects of IFN-on serum 5-HT, plasma tryptophan, serum kynurenine, the K/T quotient, and plasma CAA. Dunn tests showed (1) significantly lower serum 5-HT 2 to 4 weeks ( t = 6.93, p = 0.000008) and 4 to 6 months ( t = 8.34, p = 0.000002) after starting treatment than before, but no significant differences between the two posttreatment time points ( t = 1.42, p = 0.2); (2) significantly lower plasma tryptophan 4 to 6 months ( t = 3.97, p = 0.0008), but not 2 to 4 weeks ( t = 2.07, p = 0.05), after starting treatment than before, and no significant differences between the two posttreatment time points ( t = 1.90, p = 0.07); (3) significantly higher serum kynurenine 2 to 4 weeks ( t = 7.39, p = 0.000005) and 4 to 6 months ( t = 4.60, p = 0.0002) after starting treatment than before, and significantly higher values 2 to 4 weeks than 4 to 6 months after starting immunotherapy ( t = 2.78, p = 0.009); (4) a significantly higher K/T quotient 2 to 4 weeks ( t = 5.08, p = 0.0001) and 4 to 6 months ( t = 4.74, p = 0.0002) after starting treatment than before, and no significant differences between the two posttreatment time points ( t = 0.33, p = 0.7); and (5) significantly lower plasma CAA values 4 to 6 months ( t = 3.11, p = 0.005), but not 2 to 4 weeks ( t = 1.74, p = 0.09), after starting treatment than before, and no significant differences between the two posttreatment time points ( t = 1.37, p = 0.2). There were no significant differences in any of the variables between men and women, except for the CAA values, which were significantly ( F [1,36] = 17.4, p = 0.0003) higher in men (mean, 615 ± 113 M/L) than in women (mean, 493 ± 61 M/L). There were no significant correlations between patients' age and any of the pre-or posttreatment values of the clinical or biochemical data. Table 1 shows that the MADRS and HAM-A scores were significantly different among the three time points. The Dunn test showed (tested at p = 0.0166 after p correction) significantly higher MADRS scores 2 to 4 weeks ( t = 2.64, p = 0.013) and 4 to 6 months ( t = 3.33, p = 0.003) after starting immunotherapy than before and no differences between weeks 2 and 4 versus months 4 to 6 ( t = 0.7, p = 0.5). Dunn tests showed a trend toward a significantly higher HAM-A score 2 to 4 weeks after starting IFN-therapy ( t = 2.31, p = 0.027) and significantly higher HAM-A scores 4 to 6 months ( t = 2.69, p = 0.012) after starting immunotherapy than before.
Results
Discussion
A first finding of this study is that immunotherapy with IFN-significantl y increased the MADRS and HAM-A scores within 1 month after starting therapy and that the depression and anxiety scores further increased during treatment. These findings are in agreement with previous reports showing that IFN--based immunotherapy increases depressive ratings and induces full-blown major depression in a considerable number of patients. The second major finding of this study is that serum 5-HT was significantly diminished during treatment with IFN-. IFN-administration significantly reduces in a dose-dependent manner the 5-HT in the frontal cortex, midbrain, and striatum and may increase 5-HT transporter mRNA and 5-HT transporter uptake activity. Thus, these studies suggest that IFN--induced depressive symptoms may arise through depletion of peripheral and central 5-HT, which in part may be related to changes in the 5-HT transporter transcription and the uptake activity of the 5-HT transporter. The third major finding of this study is that plasma tryptophan was significantly reduced and serum concentrations of kynurenine and the K/T quotient were significantly increased during immunotherapy with IFN-, suggesting an increased catabolism of tryptophan to kynurenine.
